2 recruiting, 1 unknown. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 2, Unknown 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Ovarian Carcinosarcoma: new trials by email Literature Review of Ovarian Carcinosarcoma trials Research Report on Ovarian Carcinosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 3 | Recruiting | NRG Oncology | 880 | 2025-03-12 | 2026-11-09 |
| Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs - Ovarian Carcinosarcoma, Endometrial Carcinosarcoma | Phase 2 / Phase 3 | Recruiting | ARCAGY/ GINECO GROUP | 138 | 2020-07-15 | 2026-09-09 |
| Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Carboplatin, Ifosfamide, Paclitaxel - Mixed Mesodermal (Mullerian) Tumor, Ovarian Carcinosarcoma | Phase 3 | Unknown | GOG Foundation | 637 | 2009-08-17 | 2021-09-30 |
Ovarian Neoplasms (2) · Carcinosarcoma (1) · Fallopian Tube Neoplasms (1) · Neoplasms (1)
Adnexal Diseases (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Gonadal Disorders (2) · Neoplasms by Site (2) · Ovarian Diseases (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Fallopian Tube Diseases (1) · Neoplasms (1)
Antineoplastic Agents (1) · Bevacizumab (1) · Carboplatin (1) · Disulfides (1) · Ifosfamide (1) · Immunoglobulin G (1) · Magnetic Resonance Spectroscopy (1) · Paclitaxel (1) · Specimen Handling (1) · Taxes (1) · dostarlimab (1) · niraparib (1) · olaparib (1)
ARCAGY/ GINECO GROUP (1) · GOG Foundation (1) · NRG Oncology (1)
United States (2) · France (1) · Italy (1) · Japan (1) · Puerto Rico (1) · South Korea (1) · Spain (1)
Matthew A Powell (1) · Ying Liu (1)
U10CA180868 (2), U10CA027469 (1)